Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8096)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR CUM CHAIRMAN OF THE AUDIT COMMITTEE, MEMBER OF THE NOMINATION COMMITTEE AND THE REMUNERATION COMMITTEE

The Board announces that Dr. LAM Lee G. has been appointed as an independent non-executive director of the Company with effect from 1 July 2014. Dr. Lam has also been appointed by the Board as a member and chairman of the Audit Committee, a member of the Nomination Committee and a member of the Remuneration Committee of the Board with effect from the same date.

Reference is made to the announcement of the Company dated 4 April 2014.

The board of directors ("Board") of Ruifeng Petroleum Chemical Holdings Limited ("Company") is pleased to announce that Dr. Lam Lee G. ("Dr. LAM") has been appointed an independent non-executive Director and chairman of the audit committee, member of the remuneration committee and nomination committee of the Board with effect from 1 July 2014 and to comply with Rules 5.05(1) and 5.28 of the Rules (the "GEM Listing Rules") Governing the Listing of Securities on the Growth Enterprise Market ("GEM") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

Dr. LAM Lee G., aged 54, has been appointed as an independent non-executive Director of the Company with effect from 1 July 2014. Dr. Lam has also been appointed by the Board as a member and chairman of the Audit Committee, a member of the Nomination Committee and a member of the Remuneration Committee of the Board with effect from the same date.

Dr. Lam is currently Chairman – Indochina, Myanmar and Thailand (and formerly Chairman – Hong Kong), and Senior Adviser – Asia, of Macquarie Capital (Hong Kong) Limited.

Dr. Lam holds a Bachelor of Science in Sciences and Mathematics, a Master of Science in Systems Science, and a Master of Business Administration Degree, all from the University of Ottawa in Canada, a Post-graduate Diploma in Public Administration from Carleton University in Canada, a Post-graduate Diploma in English and Hong Kong Law and a Bachelor of Law (Hons) from Manchester Metropolitan University in the United Kingdom, a PCLL in law from the City University of Hong Kong, a Certificate in Professional Accountancy from the Chinese University of Hong Kong SCS, a LLM in law from the University of Wolverhampton in the United Kingdom, a Master of Public Administration and a Doctor of Philosophy Degree from the University of Hong Kong.

Dr. Lam has over 30 years of experience in multinational general management, management consulting, corporate governance, investment banking, direct investment and fund management across the telecommunications, media and technology (TMT), consumer/healthcare, infrastructure/real estates, resources/energy and financial services sectors, and he also serves on the board of several publiclylisted companies and investment funds in the Asia Pacific region. Having served as a Part-time Member of the Central Policy Unit of the Government of the Hong Kong Special Administrative Region for two terms and the Legal Aid Services Council, Dr. Lam is a Member of the Jilin Province Committee (and formerly a Specially-invited Member of the Zhejiang Province Committee) of the Chinese People's Political Consultative Conference, a Vice Chairman of Liaoning Chinese Overseas Friendship Association, a Member of the New Business Committee of the Financial Services Development Council (FSDC), a Member of the Derivatives Market Consultative Panel of Hong Kong Exchanges and Clearing Limited (HKEx), a Member of the Hong Kong Institute of Bankers, a Member of the World Presidents' Organization, a Member of the Chief Executives Organization, a Fellow of the Hong Kong Institute of Directors and the Hong Kong Institute of Arbitrators, an Accredited Mediator of the Centre for Effective Dispute Resolution (CEDR), a Member of the General Committee and the Corporate Governance Committee of the Chamber of Hong Kong Listed Companies, a Board Member of the Australian Chamber of Commerce in Hong Kong and Macau, a founding Board Member and the Honorary Treasurer of the Hong Kong-Vietnam Chamber of Commerce, a founding Member of the Hong Kong-Korea Business Council, a Vice President of the Hong Kong Real Property Federation, and Chairman of Monte Jade Science and Technology Association of Hong Kong.

Dr. Lam is currently an independent/non-executive director of the following companies which shares are quoted on the stated stock exchange:—

On the Hong Kong Stock Exchange: CSI Properties Limited (Stock Code: 497), Far East Holdings International Limited (Stock Code: 36), Glorious Sun Enterprises Limited (Stock Code: 393), Hutchison Harbour Ring Limited (Stock Code: 715), Imagi International Holdings Limited (Stock Code: 585), Mei Ah Entertainment Group Limited (Stock Code: 391), Sunwah Kingsway Capital Holdings Limited (Stock Code: 188), Vongroup Limited (Stock Code: 318);

On the Stock Exchange of Singapore: Next-Generation Satellite Communications Limited (Stock Code: B07), Rowsley Limited. (Stock Code: A50) and Asia-Pacific Strategic Investments Limited (Stock Code: 5RA), Top Global Limited (Stock Code: 519);

On the Toronto Stock Exchange: Sunwah International Limited (Stock Code: TSX SWH);

On the Stuttgart Stock Exchange: Vietnam Equity Holding (Stock Code: 3MS), Vietnam Property Holding(Stock Code: 3MT); and

On the Australian Stock Exchange: Coalbank Limited (Stock Code: ASX CBQ).

Within the past three years Dr. Lam was an independent non-executive director of the following companies which shares are quoted on the stated stock exchange:—

On the Hong Kong Stock Exchange:

China Communication Telecom Services Company Limited (Stock Code: 8206), Wai Chun Mining Industry Group Co. Ltd. (Stock Code: 660), Mingyuan Medicare Development Company Limited (Stock Code: 233);

On the Malaysian Stock Exchange:

TMC Life Sciences Berhad (Stock Code: MYX0101); and

On the NASDAQ Exchange:

CDC Software Corporation (Stock Code: CDCS).

There is no service agreement entered into between the Company and Dr. Lam and Dr. Lam's appointment is deemed, until otherwise subsequently determined, to be continuing. Dr. Lam's appointment is subject to the requirements on the re-election and retirement by rotation of directors at the subsequent general meetings of the Company in accordance with the GEM Listing Rules and provisions of the Company's articles of association. Dr. Lam will receive a director's fee of HK\$15,000 per month which is recommended by the Remuneration Committee of the Company and the Board having regard to his qualifications, experience, duties and responsibilities and the prevailing market conditions.

Other than the fact that Dr. Lam is currently an independent director of Coalbank Limited (of Australia) where Mr. Chan Wai Lun, Anthony, executive Director and Chairman of the Company, is an executive director and chairman of the board, Dr. Lam is not related to any other director, senior management or substantial or controlling shareholders of the Company.

As at the date of this announcement, within the meaning of Part XV of the SFO, Dr. Lam has no interests in the shares of the Company.

Save as disclosed in this announcement, there is no information relating to the appointment of Dr. Lam that need to be brought to the attention of the shareholders of the Company or is required to be disclosed pursuant to rule 17.50(2).

The Board takes the opportunity to warmly welcome Dr. Lam to join the Company,

As disclosed in the announcements of the Company dated 2 April 2013 and 25 September 2013, trading in its shares on the Stock Exchange was suspended with effect from 9:00 a.m. on 2 April 2013 until the conditions of the Stock Exchange as disclosed in the announcement dated 25 September 2013 are satisfied. Trading of the shares of the Company will remain suspended until further notice.

Shareholders of the Company and the potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of

Ruifeng Petroleum Chemical Holdings Limited

Chan Wai Lun, Anthony

Chairman

Hong Kong, 30 June 2014

As at the date of this announcement, the Board comprises Mr. Chan Wai Lun, Anthony (Chairman), Mr. Yue Wai Keung (Chief Executive Officer) and Mr. Guo Jingsheng as executive Directors; Mr. Chan Kwan Pak as non-executive Director; and Dr. Chen Tzyh-Trong and Dr. Lee Chung Mong as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquires, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM Website at www.hkgem.com for a minimum period of seven days from the day of its publication and on the website of the Company at www.ruifengholdings.com.